Celyad Oncology SA
CLYYF
$0.25
-$0.10-28.57%
OTC PK
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 119.62% | 61.00% | 16.19% | 25.07% | 31.05% |
| Total Depreciation and Amortization | -70.39% | -51.31% | -38.31% | -45.51% | -49.51% |
| Total Amortization of Deferred Charges | -25.22% | -6.01% | 19.79% | 19.79% | 19.79% |
| Total Other Non-Cash Items | -5,282.38% | -2,940.79% | -98.73% | 80.75% | 87.69% |
| Change in Net Operating Assets | -797.23% | 45.93% | 96.76% | 97.11% | 97.27% |
| Cash from Operations | -27.11% | 13.29% | 36.51% | 53.13% | 62.62% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | 21,554.32% | 7,854.05% | -42.35% | -97.82% | -98.88% |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | 100.00% | 100.00% | 23.95% | -238.20% |
| Cash from Investing | 3,251.84% | 520.73% | 102.21% | 66.90% | -125.38% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 24.55% | 6.60% | -15.44% | -15.30% | -15.17% |
| Issuance of Common Stock | -- | -89.83% | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -82.38% | -74.50% | -63.61% | 73.91% | 31,400.00% |
| Cash from Financing | -49.28% | -85.08% | -94.23% | -82.63% | -68.15% |
| Foreign Exchange rate Adjustments | 288.37% | 213.64% | -- | -660.00% | -330.00% |
| Miscellaneous Cash Flow Adjustments | 0.00% | 100.00% | 100.00% | 120.00% | -- |
| Net Change in Cash | 12.39% | -396.18% | -536.51% | -92.46% | 48.34% |